ECSP055972A - 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas - Google Patents

4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas

Info

Publication number
ECSP055972A
ECSP055972A EC2005005972A ECSP055972A ECSP055972A EC SP055972 A ECSP055972 A EC SP055972A EC 2005005972 A EC2005005972 A EC 2005005972A EC SP055972 A ECSP055972 A EC SP055972A EC SP055972 A ECSP055972 A EC SP055972A
Authority
EC
Ecuador
Prior art keywords
chinoclincarbonitrils
metoxifenil
dicloro
alcoxi
ischemical
Prior art date
Application number
EC2005005972A
Other languages
English (en)
Inventor
Diane Harris Boschelli
Margareth Maria Zaleska
Frank Charles Boschelli
Kim Timothy Arndt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP055972(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ECSP055972A publication Critical patent/ECSP055972A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Los compuestos de la Fórmula (I), en donde X es N, CH; n es un número entero de 1 a 3; y R y R' independientemente son alquilo de 1 a 3 átomos de carbono, y sales farmacéuticamente aceptables de dichos compuestos, con la condición de que cuando n es 1, X no puede ser N; son útiles para la inhibición de la permeabilidad vascular causada por enfermedad, lesión o algún otro trauma.
EC2005005972A 2003-02-21 2005-08-19 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas ECSP055972A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44931603P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
ECSP055972A true ECSP055972A (es) 2006-01-16

Family

ID=32927510

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005972A ECSP055972A (es) 2003-02-21 2005-08-19 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas

Country Status (19)

Country Link
US (1) US20040229880A1 (es)
EP (1) EP1594502A1 (es)
JP (1) JP2006522023A (es)
KR (1) KR20050102133A (es)
CN (1) CN1750824A (es)
AR (1) AR043253A1 (es)
AU (1) AU2004216235A1 (es)
BR (1) BRPI0407441A (es)
CA (1) CA2516418A1 (es)
CO (1) CO5640114A2 (es)
CR (1) CR7931A (es)
EC (1) ECSP055972A (es)
MX (1) MXPA05008706A (es)
NO (1) NO20054070L (es)
RU (1) RU2005129333A (es)
TW (1) TW200423938A (es)
UA (1) UA80472C2 (es)
WO (1) WO2004075898A1 (es)
ZA (1) ZA200506621B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06004744A (es) * 2003-11-06 2006-07-05 Wyeth Corp 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica.
MX2007004833A (es) * 2004-10-22 2007-05-16 Wyeth Corp 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolin ocarbonitrilos para el tratamiento de lesion isquemica.
RU2007148072A (ru) * 2005-07-01 2009-08-10 Вайет (Us) Кристаллические формы 4-[(2,4-дихлор-5-метоксифинил)амино]-6- меокси-7-[3-(4-метил-1-пиперазинил)пропокси]-3-хиналинкарбонитрил и способы их получения
BR112013002182B8 (pt) 2010-07-30 2023-02-28 Oncotherapy Science Inc Compostos derivados de quinolina, composição farmacêutica, inibidor de melk, agente modulador de expressão de melk, agente antitumor, agente terapêutico e/ou preventivo para uma doença que envolve a superexpressão de melk contendo os mesmos e uso dos referidos compostos
CN103772392A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
IN2014CH00840A (es) * 2014-02-20 2015-09-18 Apotex Inc
US10231965B2 (en) 2014-02-20 2019-03-19 Ignyta, Inc. Molecules for administration to ROS1 mutant cancer cells
US20160256457A1 (en) * 2014-06-10 2016-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for treating or preventing acute vascular leak
JP6744309B2 (ja) 2014-12-02 2020-08-19 イグニタ,インコーポレイテッド 神経芽細胞腫の治療のための併用
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017106492A1 (en) 2015-12-18 2017-06-22 Ignyta, Inc. Combinations for the treatment of cancer
CN107814769B (zh) * 2016-09-14 2021-05-07 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
BR112020000793A2 (pt) 2017-07-19 2020-07-14 Ignyta, Inc. composições farmacêuticas e formas de dosagem
JP7311498B2 (ja) 2017-10-17 2023-07-19 イグナイタ インコーポレイテッド 薬学的組成物および剤形
CN111646940B (zh) * 2019-03-04 2024-01-30 鲁南制药集团股份有限公司 一种博舒替尼中间体的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) * 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6521618B2 (en) * 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
CA2500368A1 (en) * 2002-10-04 2004-04-22 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Inhibition of src for treatment of reperfusion injury related to revascularization

Also Published As

Publication number Publication date
MXPA05008706A (es) 2005-10-05
JP2006522023A (ja) 2006-09-28
CA2516418A1 (en) 2004-09-10
NO20054070L (no) 2005-11-14
TW200423938A (en) 2004-11-16
CO5640114A2 (es) 2006-05-31
BRPI0407441A (pt) 2006-01-31
US20040229880A1 (en) 2004-11-18
CR7931A (es) 2006-02-07
ZA200506621B (en) 2008-02-27
AR043253A1 (es) 2005-07-20
NO20054070D0 (no) 2005-09-01
EP1594502A1 (en) 2005-11-16
UA80472C2 (en) 2007-09-25
AU2004216235A1 (en) 2004-09-10
KR20050102133A (ko) 2005-10-25
RU2005129333A (ru) 2006-01-27
WO2004075898A1 (en) 2004-09-10
CN1750824A (zh) 2006-03-22

Similar Documents

Publication Publication Date Title
ECSP055972A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-3-quinoclincarbonitrilos para el tratamiento de lesiones isquémicas
ECSP066548A (es) 4-anilino-3-quinolincarbonitrilos para el tratamiento de leucemia mielogena cronica
UY27918A1 (es) Derivados de benzodioxol
PE20020476A1 (es) Derivados de glucopiranosiloxibencilbenceno y composiciones farmaceuticas que comprenden los mismos
UY26512A1 (es) Inhibidores no peptídicos de la unión celúlar dependiente de vla - 4 útiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias
UY28135A1 (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal
CR10127A (es) Agente para la prevención o tratamiento de neuropatías (divisional exp. 7849)
DOP2001000170A (es) Derivados de tiofeno utiles como agentes anticancesoros
PA8557001A1 (es) Nuevos derivados de pirrolidina
UY26086A1 (es) Procedimientos e intermedios para preparar compuestos anticancerosos
BRPI0412347A (pt) 2-aminofenil-4-fenilpiridinas como inibidores de quinase
UY27234A1 (es) Inhibidores novedosos de tirosina cinasa
ES2126068T3 (es) Derivados de estilbeno citotoxicos y composicion farmaceutica que los contiene.
UY27872A1 (es) Inhibidores de caspasa y usos de los mismos.
CR10376A (es) Derivados de terfenil para el tratamiento de la enfermedad de alzheimer
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
ATE279192T1 (de) Die verwendung eines benzimidazoles zur herstellung eines medikamentes zur krebsvorbeugung
UY27018A1 (es) Derivados de la pirimidina
MX2007011814A (es) Compuestos citoesqueleticos activos, composiciones y usos.
ECSP077385A (es) 4-[(2,4-dicloro-5-metoxifenil)amino]-6-alcoxi-7-etinil-3-quinolinocarbonitrilos para el tratamiento de lesión isquémica
AU8519601A (en) 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents
PA8531601A1 (es) Nuevos heteroaromatos
NO20053997D0 (no) Oligosaccharidderivat
CR6503A (es) Derivados de- 1-trifluorometil-4-hidroxi-7-piperidinil-aminometiclcromano
AR037140A1 (es) Un compuesto de aminopirrol, su utilizacion, un procedimiento para producirlo y una composicion que lo comprende